Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Drilon

Showing results (201-210 of 268) with videos related to

Pageof 27
Sort By:
British Journal of Cancer|September 4, 2021
NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer typesChristian Rolfo, Alexander Drilon, David Hong, et al.
JAMA Oncology|July 26, 2019
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With NivolumabSuzanne L Topalian, F Stephen Hodi, Julie R Brahmer, et al.
Cancer Discovery|November 30, 2018
A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105Alexander Drilon, Siqing Fu, Manish R Patel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 11, 2020
<i>MET</i> Exon 14-altered Lung Cancers and MET Inhibitor ResistanceRobin Guo, Michael Offin, A Rose Brannon, et al.
Nature Medicine|April 28, 2022
Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CASmita S Chandran, Jiaqi Ma, Martin G Klatt, et al.
Nature Medicine|February 4, 2026
Repotrectinib in NTRK fusion-positive advanced solid tumors: a phase 1/2 trialBenjamin Besse, Jessica J Lin, Lyudmila Bazhenova, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2022
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid TumorsGeorge D Demetri, Filippo De Braud, Alexander Drilon, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 19, 2025
Clinical Significance of MTAP Deletions and their Overlap with Concurrent Oncogenic Driver Alterations Including EGFR in Non-Small Cell Lung CancerJessica S Ross, Rohit Thummalapalli, Christopher A Febres-Aldana, et al.
Cancer|September 28, 2023
Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomasShivaani Kummar, Lin Shen, David S Hong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2022
Correction: Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Solid TumorsGeorge D Demetri, Filippo De Braud, Alexander Drilon, et al.
Pageof 27

Showing results (201-210 of 268) with videos related to

Sort By:
Pageof 27
British Journal of Cancer|September 4, 2021
NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer typesChristian Rolfo, Alexander Drilon, David Hong, et al.
JAMA Oncology|July 26, 2019
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With NivolumabSuzanne L Topalian, F Stephen Hodi, Julie R Brahmer, et al.
Cancer Discovery|November 30, 2018
A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105Alexander Drilon, Siqing Fu, Manish R Patel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 11, 2020
<i>MET</i> Exon 14-altered Lung Cancers and MET Inhibitor ResistanceRobin Guo, Michael Offin, A Rose Brannon, et al.
Nature Medicine|April 28, 2022
Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CASmita S Chandran, Jiaqi Ma, Martin G Klatt, et al.
Nature Medicine|February 4, 2026
Repotrectinib in NTRK fusion-positive advanced solid tumors: a phase 1/2 trialBenjamin Besse, Jessica J Lin, Lyudmila Bazhenova, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2022
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid TumorsGeorge D Demetri, Filippo De Braud, Alexander Drilon, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 19, 2025
Clinical Significance of MTAP Deletions and their Overlap with Concurrent Oncogenic Driver Alterations Including EGFR in Non-Small Cell Lung CancerJessica S Ross, Rohit Thummalapalli, Christopher A Febres-Aldana, et al.
Cancer|September 28, 2023
Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomasShivaani Kummar, Lin Shen, David S Hong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2022
Correction: Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Solid TumorsGeorge D Demetri, Filippo De Braud, Alexander Drilon, et al.
Pageof 27